Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Akero Therapeutics, Inc.

https://akerotx.com/

Latest From Akero Therapeutics, Inc.

Akero Sees Across-The-Board NASH Benefit With Efruxifermin, But Faces Competition

At EASL 2021, Akero presented efruxifermin data showing benefit in cirrhotic NASH patients and strong liver fat reduction, but may be challenged in the FGF21 analog class by 89Bio.

Business Strategies Clinical Trials

NGM Phase IIb NASH Failure Could Darken Competitors’ Prospects

NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.

Clinical Trials Business Strategies

89bio Hopes Akero’s Success In Cirrhotic NASH Is Positive For FGF21 Class

Analysts say the cirrhosis-reversing benefit seen with Akero’s efruxifermin portends well for the entire class, and that 89bio might differentiate on safety, tolerability and dosing frequency.

Clinical Trials Business Strategies

Akero First To Show Benefit In Cirrhotic NASH Patients

Although the data are from a small cohort of an ongoing study, Akero’s FGF21 analog reduces fibrosis score by at least one stage in 33% of cirrhotic NASH patients.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register